Gabapentin, a relatively new anti-epileptic drug (liED), is emerging as a therapeutic option JOr treatment refractory and rapid-cycling bipolar illnesses. Pharmacotherapy JOr bipolar disorders traditionally involves oalproate, carbamazapine, or lithium, drugs which are associated with numerous adverse effects. Conversely, gabapentin has an attractive pharmacokinetics profile and relativelyje w side effects. There are no large randomizedcontrolled clinical trials to date examining gabapentin's role in mood stabilization. However, informal reports have cited encouraging results in up to 80% ifpatients and general tolerance to side ifJects. Thesefin dings make the new drug a possible choicefor patients who haveJailed to respond to traditional agents or developed side effects which interfere with medication compliance.
METHODOLOGY
A literatu re search of th e Med lin e and Silver Platter dat ab ases was pe rform ed. English la ngu age articles pu blish ed be twee n 1990-1997 were reviewed . Keywords " ga ba pe ntin," " bipola r," "e pile psy," a nd " psychia t ry" were used in va rious combinations. All articl es whi ch addressed t he use of ga ba pe n tin in human subj ects we re conside re d . Review of citations in t hes e articles led to furth e r referen ces to th e clinical use of ga ba pe n tin. All cita tions relat ed to th e use of ga ba pentin in th e t re a t me n t of affec tive di sorders a re included in thi s review. Othe r art icles which add ress clinica lly usefu l ph arm acological issu es a re a lso includ ed. CHEMISTRY Ga ba pen tin (Ne uro n tin) is a cyclic gamm a-amino butyri c ac id (GABA) a nalog ue whi ch may a lter GA BA transmiss ion in t he centra l nervous syste m (I ). The mol ecul e incorporates a lipophilic cyclohe xa ne rin g into its s t ruc t u re, whi ch a llows gabapentin, un like GA BA, to cross th e blood-brain barrier. P ha rmacokinetic a nd pharm acodynamic inve stigations have la rgely re lied on st udy of a nimals. The drug was initiall y d evelop ed as a spas mo lyt ic bu t dem on strat ed e ffec tive a n tico nvu lsant properties, and thus e n te re d th e ph armaceutica l market as a n AED (2) .
Early resea rch in to gabapentin's m ech anism of ac tion fa iled to provid e strong evide nce of GA BAergic ac tivity. It do es not a ppea r to sig n ificant ly bind to GABA-A, GA BA-B, glu tama te, glycin e, or benzodiazapin e receptor s; it does not a ffec t volt ag e COOH Gabapentin FIGURE 1. Structure of Gabapentin ga te d sod ium or calciu m channe ls, a nd it does not eleva te GABA conce n t ra tion in nerve terminal s ( 1, 3) . How ever, ad m inis t ra tion of ga ba pe ntin has been ass ocia te d with in cr eased GABA conce n t ra tion in th e subs tan tia nigra , a region rep eated ly indi cated in th e activity ofGABAergi c anticonvulsants (4) .
G ab ap entin is tran sport ed ac ross e nte ric m embran es a nd most likely through t he blood-brain ba rri er a nd into neuron s by a n L-amin o ac id carrier (2, 5) . It s binding site has been recen tly identified as a subu nit of a calc ium cha nn el on neuronal ce ll sur faces (3, 6) . Gab apentin increases th e ra te of syn t hes is and accumu lat ion of GABA, decr eases th e release of mon oamin es (do pa m ine, nor e pin eph ri ne, a nd serotonin), a nd weakly inhibits GABA-transaminase, an e nzyme which degr ad es GABA into ot he r a m ino ac ids (3, 4) .
PHARMACOKINETI CS
Gaba pe n tin is becomi ng popu la r a mo ng pracu t io n e rs du e to its favorabl e ph a rm acokinetics profil e. It is effic ie nt ly a bsorbed in th e gu t following or a l ingestion.
Th e drug has a hal f-life of 5-9 hours, rea ch es peak plasm a conce ntrat ion in 2-3 hours, a nd ac hieves ste ady sta te in 1-2 days. It is wat e r-soluble an d non-pr ot ei n-bound , bu t is di stribut ed th rou gh out th e bod y (includ ing th e CNS) by means of protein transport. Gabap entin is not meta bolized , is comple tely elim inat ed by th e kid neys, a nd does no t interact wit h hep at ic enzymes. T hese q ua liti es t heoreti ca lly elim ina te pot e ntial int e racti on s wit h ot her m ed ica ti ons (2, 5, 7) .
CLINICAL USE
Co n trolled clinical t rials of ga ba pe nti n in t he t reat me nt of psychiatric dis orders have not been pe rformed . Seve ra l anecdotal reports of use exist in th e medi ca l lit erature (8) (9) (10) (11) (12) , incl udi ng a growing nu mb er of documents pertaining to ga ba pe ntin 's ro le in bipo la r illn ess. Howeve r, mos t dat a regarding t he drug's efficacy a nd safety a ppear in rep ort s of ga ba pe n tin's use as a n an ticonvulsan t. T his informa tion has se rved as a valuabl e guide to pr eliminary st ud ies in th e ment al health are na .
Th ree large ra nd omized cont rolled clin ica l t ria ls have eva luat ed th e efficacy and safety of adj unc tive ga ba pe n tin th erapy in trea ting refractory e pile psy: th e UK G ab ap entin St udy G roup ( 1990), the US G ab ap e nt in St udy Group No.5 (1993), a nd th e Int ernation al Gab apentin St udy Group (1994) . Dr ug dosages ranged from 600 mg/d to 1800 mg/d, with th e most effective dosin g regim en re ported to be 1800 mg/d. Th e percent ages of patients in whom se izure fre quency decreased at lea st 50% (respo nde rs) we re 25%, 26%, and 28%, resp ectively ( 19) . Morris has since report ed a re trosp ective a nalysis of 100 pati ents on ga ba pe n tin, 72 of whom experien ced a greate r th an 50% reducti on in se izu re fre q ue ncy. Th e mean drug dos e in this pati ent population was 210 7 mg/d; 37 of th e 72 who resp onded (5 1%) were ta king 1800 mg/d or less. The remaining patients took 1800-3600 rug/day (20) .
Data regarding th e rol e of ga ba pe ntin in th e t reat m e nt of bipolar disord ers is pr eliminary, ye t e nco u raging . In on e retrosp ecti ve st udy of bip ola r pa tie n ts who had fa iled to respond to tradition al mood stabilize rs or d evelop ed intolera ble sid e effects from th es e agents, 92% responded positively to ga ba pe nt in (14) . All other publ ish ed studies, consisting of op en trials whi ch have includ ed ga ba pe nt in bot h as monoth erapy and in addition to other psychotropic m edi cation s, have re ported effect ive improvem ent in th e majority of patients (13,15 ,17 ,18) . Mo st pati ents have d isp layed noticeable improvem ent in cycling activity with 200-3600 mg/d , th ou gh doses as low as 33 mg /d a nd as high as 4900 mg/d ha ve been re por te d ( 13, 15) . Ga ba pen tin may also have antidepressant effec ts: patients on th e new AED have noted im prove me nt in mood , m emory att ention , e ne rgy, slee p, and libido ( 10, 13, 17) . Elevation in mood whi ch accompanied th e transition fro m t radition al AE Ds to gabapentin, howeve r, may have resulted from di scontinuati on of th e se dating side effects of th e tradi tional agen ts . Further st udy is need ed to det ermine if ga ba pe nt in has inh e re nt antidepressa nt effec ts.
SAFETY
Gab apent in has proven its el f to be a relativel y sa fe drug. The most commonlye ncoun te re d side effec ts a re so m no le nce (24%), di zzin ess (20%), ataxia (17%), and fatigu e (14%) (19) . Less fr equent sid e effor ts include involuntary twitches (1.3%), rash (0.5%), leukopeni a (0.2%) , azo te m ia (0. 1%), t hrom bocyto pe nia (0. 1%), stutterin g (I case), a nd weight ga in (19, 21, 22) . The re have been several report ed cas es of hypomania and/or in cr eased mood cycling ( 14, 15, 17, 23) a nd th e re has be en on e cas e of oculogyri c crisis whi ch was emerge n tly reversed wit h a ben zodi azep in e (22) .
A th erap eutic range for ga ba pe ntin has ye t to be es ta blishe d . Peak steady-state plasma levels of th e drug ave rage a bou t 4 mi crograms/ml (7) . The re has bee n on e report ed case of overdose, in whi ch a 16-year-old in gest ed 163 ca ps u les (49,900 mg) without e me sis or return of pill frag me n ts on gas tr ic lavage. H er plasma gabapentin level was 62 mi crogram s/ml at 8.5 hours afte r ingesti on. She was letha rgic, but was easily aroused and a ble to co nve rse normall y; by 18 hours post -in gesti on, sh e was al ert and without com pla in ts (24) . This case report is cons iste nt wit h a nimal toxicity test s, in whi ch mi ce a nd rats experie nce d only a taxia a nd labored breat hing at maximum dose of 2000 mg/k g IV a nd 8000 mg/k g PO. No ne of t he animals expired (24) .
Gabapentin has seve ral prop erties whi ch sign ifican tly reduce its pot ential for int eraction with other drugs. It is non-prot ein-bound, it does not affect hep atic e nzym e ac tivity, and it has no met ab olites (2) . Alt ho ug h clinica l trials have not rep orted a ny cases of drug-drug inte racti on s invo lving gabape ntin (20) , a nd so me so urces have suggeste d th at suc h int e racti ons are impossibl e (25, 26) , several rep ort s have suggested th at th e dru g m ay occas ionally affect or be influe nced by ot he r medi cation s.
In on e s tudy, a th erap eutic dos e of a lu m in um a nd magn esium hydroxide (M aa lox) , adm inis te re d concom ita ntly with or shortly afte r 400 mg of ga bapentin, reduced th e bioavail ability of th e latt er by 20% (2 7). C ime tidin e has report edl y decr eased t he renal clearance of ga ba pe ntin by a cli nica lly significant a moun t (7) . The re ha s been one case rep ort of ga ba pe n tin int e racting with phenytoin. A patient wit h a lon g hist ory of com plex partial a nd secondarily gen eralized seizures, who was on three AED 's, began taking ga bape nt in. Hi s plasm a phenytoin con centration subseque ntly incr eased from 42 to 177 mi cro gr am slL a nd returned to baseli ne upon removal of th e new drug (28) . Finally, ga ba pe ntin has been assessed as unlikely to ca use contracep tive failure wh en tak en with oral co ntrace ptives (7) .
Th ere a re few rep orts of pr egn ant wom en ta king gabape ntin. No teratogeni c effects have bee n not ed in a ny of t he 10 reports on file (29) . The drug is, however, fe totoxic in rode n ts, associa te d with del ayed oss ification, hydrouret er, and hydron ephrosis a t doses up to four tim es great e r t ha n rela tive standard human dosages (i.e. 3600 m g/d ). There was a lso an incr eased incid en ce of pa ncr eatic acinar cell tumors in mal e rats a t high do ses, though th ei r life spa n was not a ffec ted by th e neoplasms (30). Potential uses of ga ba pe ntin in th e pedi at ric affect ive d isorders popu lations have ye t to be dete rmined.
DOSI G
Formal dosin g guide lines a re not ava ila ble for th e use of gabape n tin in bipol a r d isord e rs. Maint en an ce doses for se izure con trol ra nge fro m 900-2400 mg/d (2, 6, 19, 26) and pr eli mi na ry t rial s of ga bapen tin for mood stabilization seem to sugge st a sim ila r dos e range. The drug's re la tively sho rt hal f-life ne cessit at es T ID ad m inist ra tion. Gabapentin treat ment for refract ory seizu res is gen era lly init iat ed with 300 mg once on t he first day, 300 mg twice on t he second day and 300 mg three tim es on th e third day, wit h subse q ue nt incr eases in TID dose as req uired for symptom con t rol (2, 19) .
O f some clini cal significa nce is t he fact th at all stu di es to da te exa mining ga ba pe nt in in th e t reatm ent of bip ola r illness have inclu d ed patients who responded to a dose less t han 900 mg/d (13) (14) (15) (16) (17) (18) . In on e study of 28 patient s, th e mean gabapen tin dos e was 539 mg/d ( 15) . H ence, increasing dos es by 200 mg inst ead of300 mg may be more appropria te for mood stabi lization.
DISCUSSIO N
All of th e m edi cation s presently used to treat bipolar d isor de r have significa nt side effects which impact both qu ality of life and th erapeutic com plia nce. Unfortu-nat ely, in this patient population , di ssatisfaction wit h trea t m e n t regimen s has th e pot ential to sign ifica n tly wor sen th e patient 's clin ica l course by magnifying feelings of hop elessn ess in a d epressed pa tie nt. Gab ape ntin hold s promise as an adj unc tive for m of treatment whi ch has few inh erent di sadvant ages and littl e cha nce of interacting with ot he r drugs. It s favo ra ble ph armacok in etics profi le is unique a mong mood stabilize rs . Th e drug has relat ively few side effects, most of which are beni gn in natu re. It s possibl e a ntide pressant effec ts a nd hypoma nic sid e effe cts need fu rth er st udy. It has thus fa r demon strat ed low toxi cit y a t t he ra pe u tic dos es and in ove rdo se. Gabape nt in has displ ayed clinical efficacy in up to 80% of bipolar patien ts in preliminary clinical t rial s, a nd is presently undergoin g investigation as a possibl e age n t in th e treatment of mi gr ain e headach es, chronic pain, a nd behavioral di sorde rs. Few reports of ga ba pe ntin's use in human pr egn ancy ex ist, and animal studies ha ve been somewhat dis couragin g.
Current psychi at ric use of ga ba pe ntin is restrict ed to pa tie n ts who have fai led to respond to traditional age nts or d eveloped intol erabl e side effects from t he m. Th e upper limit of th e drug' s th erapeutic range mu st be established. P roble ms with m edi cation com plia nce m ay be improved throu gh th e d evelopm e n t of an exte nde dre lease or dep ot form of ga ba pe ntin. A large, multi cen ter, randomized, controlled clinica l trial has ye t to be performed.
CONCLUS IONS
Gab apen tin is a GABA a na log ue a nd new AE D whi ch has th e unique a bility to cross t he blood-brain ba r rier. It appears to influence ne u ro psychologica l ac tivity by ac ting on calciu m chan nels in th e CNS. It has a favorabl e ph armacok in etics pro file an d is provin g to be re la tively sa fe in clinica l practice. The drug has displayed both mood-stabilizing a nd poss ible an ti-de pressant act ivity in pr eliminary tri al s, and is associated with a relatively beni gn side profile . Fu rt he r study of thi s new AED is clea rly need ed.
